Top Markets
Coin of the day
Rafael Holdings, Inc. Rafael Holdings, Inc.

Rafael Holdings, Inc.

RFL
Rank in Stocks #21319
Rafael Holdings, Inc. holds strategic investments in both early-stage and... Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Share Price
$2.15
Last synced: 2026-08-21
Market Cap
$110.06M
Change (1 day)
13.46%
Change (1 year)
37.76%
Country
US
Trade Rafael Holdings, Inc. (RFL)

Category

Revenue for Rafael Holdings, Inc. (RFL)
Revenue in Aug 2026 TTM: 0
According to Rafael Holdings, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Rafael Holdings, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$43.64B -
US
- -
DE
$13.06B -
CN
- -
DE
$27.43B -
US